Wells Fargo & Company Has Lowered Expectations for LeMaitre Vascular (NASDAQ:LMAT) Stock Price

LeMaitre Vascular (NASDAQ:LMAT) had its price target reduced by equities researchers at Wells Fargo & Company from $97.00 to $93.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 7.12% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Barrington Research reissued an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Cantor Fitzgerald boosted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Roth Capital reiterated a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.20.

LeMaitre Vascular Stock Performance

Shares of LMAT traded up $1.22 during mid-day trading on Friday, reaching $86.82. 275,971 shares of the company’s stock traded hands, compared to its average volume of 182,389. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The business’s 50-day moving average price is $89.75 and its 200-day moving average price is $87.00. The stock has a market capitalization of $1.97 billion, a P/E ratio of 42.15, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million for the quarter, compared to analysts’ expectations of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s revenue was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. Equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Buying and Selling

In related news, Director John A. Roush sold 6,561 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 9.50% of the stock is owned by insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. boosted its position in shares of LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after buying an additional 3,248 shares during the period. US Bancorp DE raised its position in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 368 shares during the period. Northern Trust Corp lifted its stake in LeMaitre Vascular by 5.4% in the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock worth $28,993,000 after acquiring an additional 17,748 shares in the last quarter. Congress Asset Management Co. boosted its position in LeMaitre Vascular by 4.6% during the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock worth $55,973,000 after acquiring an additional 29,553 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in LeMaitre Vascular during the 2nd quarter valued at about $892,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.